Panacea Biotec Limited — Board Meeting, 14-08-2025: Outcome of Board Meeting

Panacea Biotec's Board approved its Q1 FY26 consolidated financial results. The company reported a net profit of ₹3.96 Cr, a significant turnaround from a loss of ₹15.88 Cr last year. Total income grew to ₹166.70 Cr. This profit was largely boosted by ₹11.32 Cr in exceptional income, including an ₹8.58 Cr settlement with Apotex and ₹2.74 Cr from deferred pharma brand sales. Before these exceptional items, the Group had a pre-tax loss of ₹4.76 Cr. The 41st Annual General Meeting is set for September 30, 2025.